Blood related pharmaceuticals
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.02.2025 | - | $7.25M | - |
Mentions in press and media 4
| Date | Title | Description |
| 03.02.2025 | Aplagon's €7 Million Boost: A New Dawn for Thrombo-Inflammatory Treatments | In the world of biopharmaceuticals, innovation is the lifeblood. Aplagon, a Helsinki-based company, has just secured a significant €7 million in funding. This financial injection comes at a crucial time as Aplagon pushes forward with its gr... |
| 03.02.2025 | Aplagon Raises EUR7M in Financing | Aplagon, a Helsinki, Finland-based clinical stage biopharmaceutical company, raised €7M in financing.
The round was led by new investors Fåhraeus Startup and Growth AB (FSG), and European Innovation Council (EIC) Fund, joined by Finnish inv... |
| 03.02.2025 | HealthTech Aplagon announces €7 million for thrombo-inflammatory diseases | HealthTech Aplagon, a Helsinki-based clinical stage biopharmaceutical company developing a first-in-class therapeutic APAC for thrombo-inflammatory diseases, announced today it has closed a €7 million financing.
The funding round was led by... |
| - | Aplagon | “Aplagon – Pioneering first-in-class treatments for patients with thromboinflammatory diseases” |
Reviews 0
